Prednisolone
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
Explore 27 assets in Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05320380CT.gov A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisolone (this asset) | Children's Oncology Group | P1/2 | CCC · 48 |
| Dexasone | Princess Maxima Center for Pediatric Oncology | P1/2 | CCC |
| Hydrocortisone | Children's Oncology Group | P1/2 | CCC |
| Rituximab | M.D. Anderson Cancer Center | P1/2 | CCC |
| Prednisone | M.D. Anderson Cancer Center | P1/2 | CCC |
| Nelarabine | M.D. Anderson Cancer Center | P1/2 | CCC |
| Obi 3424 | SWOG Cancer Research Network | P1/2 | CCC |
| Vincristine Sulfate | ECOG-ACRIN Cancer Research Group | P1/2 | CCC |
| Mercaptopurine Anhydrous | M.D. Anderson Cancer Center | P1/2 | CCC |
+26 more in the Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia cohort
Other indications for Prednisolone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infantile Spasms | — | P4 | BBB · 79 |
| Non-Hodgkin Lymphoma | — | P3 | BBB · 74 |
| Lymphoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisolone in Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisolone-refractory-precursor-t-lymphoblastic-lymphomaleukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →